About

Discovery Therapeutics Caribe (DTC) is a clinical-stage biotechnology company dedicated to improving the health outcomes of Americans through the development of regenerative therapies for serious and life-threatening diseases. 

DTC’s lead product is an intralesional recombinant human Epidermal Growth Factor (rhEGF) for the treatment of complex and complicated refractory neuropathic, ischemic, and neuroischemic diabetic foot ulcers (DFU).

The clinical grades of complex and complicated refractory DFUs are comparable to Wagner’s classification system grades 3 and 4; University of Texas classification system grades 2 and 3; and Wound/Ischemia/Foot Infection (WIfI) classification system stages 3 and 4. These severe ulcers exhibit an elevated risk of amputation and death. Although treatments exist, there is substantial need for improved DFU therapies.